Drug Patents Expiring in 2030

1. List of Abilify Mycite Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8847766 OTSUKA Pharma-informatics system
Mar, 2030

(7 years from now)

US8545402 OTSUKA Highly reliable ingestible event markers and methods for using the same
Apr, 2030

(7 years from now)

US8114021 OTSUKA Body-associated receiver and method
Jun, 2030

(7 years from now)

US11464423 OTSUKA In-body power source having high surface area electrode
Sep, 2030

(7 years from now)

US9941931 OTSUKA System for supply chain management
Nov, 2030

(7 years from now)

US8961412 OTSUKA In-body device with virtual dipole signal amplification
Nov, 2030

(7 years from now)

US8258962 OTSUKA Multi-mode communication ingestible event markers and systems, and methods of using the same
Nov, 2030

(7 years from now)

US8547248 OTSUKA Implantable zero-wire communications system
Dec, 2030

(7 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 13 November, 2017

Treatment: Method of using a tablet embedded with a sensor that communicates information via a signal through the body of a patient to a receiver

Dosage: TABLET;ORAL

More Information on Dosage

2. List of Acetaminophen drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741959 FRESENIUS KABI USA Paracetamol for parenteral administration
Apr, 2030

(7 years from now)

Drugs and Companies using ACETAMINOPHEN ingredient

Market Authorisation Date: 28 October, 2015

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

3. List of Acuvue Theravision With Ketotifen drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9962376 JOHNSON JOHNSON VISN Methods and ophthalmic devices used in the treatment of ocular allergies
Jun, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Feb 25, 2025

Drugs and Companies using KETOTIFEN FUMARATE ingredient

Market Authorisation Date: 25 February, 2022

Treatment: NA

Dosage: DRUG-ELUTING CONTACT LENS ;OPHTHALMIC

More Information on Dosage

4. List of Akynzeo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623826 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

US9943515 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

US8951969 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

US9186357 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

US10828297 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Dec, 2030

(7 years from now)

Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient

Market Authorisation Date: 10 October, 2014

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy

Dosage: CAPSULE;ORAL

More Information on Dosage

5. List of Akynzeo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186357 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Nov, 2030

(7 years from now)

US10828297 HELSINN HLTHCARE Compositions and methods for treating centrally mediated nausea and vomiting
Dec, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 19, 2023

Drugs and Companies using FOSNETUPITANT CHLORIDE HYDROCHLORIDE; PALONOSETRON HYDROCHLORIDE ingredient

NCE-1 date: April, 2022

Market Authorisation Date: 19 April, 2018

Treatment: Use in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

How can I launch a generic of AKYNZEO before it's patent expiration?
More Information on Dosage

6. List of Alecensa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9440922 HOFFMANN-LA ROCHE Tetracyclic compound
Jun, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 6, 2024

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 11 December, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of ALECENSA before it's patent expiration?
More Information on Dosage

7. List of Amondys 45 drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9228187 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(7 years from now)

US10287586 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10781450 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(7 years from now)

US9758783 SAREPTA THERAPS INC Antisense molecules and methods for treating pathologies
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Feb 25, 2028
New Chemical Entity Exclusivity (NCE) Feb 25, 2026

Drugs and Companies using CASIMERSEN ingredient

NCE-1 date: February, 2025

Market Authorisation Date: 25 February, 2021

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping by restoring an mrna reading frame to induce dystrophin protein production; Treatment of duchenne muscular dystrophy (dmd) in patients who have a mutation of the dmd gene that is amenable to exon 45 skipping

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

8. List of Amzeeq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8945516 JOURNEY Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
Oct, 2030

(7 years from now)

US10265404 JOURNEY Compositions, gels and foams with rheology modulators and uses thereof
Oct, 2030

(7 years from now)

US10821187 JOURNEY Compositions, gels and foams with rheology modulators and uses thereof
Oct, 2030

(7 years from now)

US10517882 JOURNEY Method for healing of an infected acne lesion without scarring
Oct, 2030

(7 years from now)

US10213512 JOURNEY Topical tetracycline compositions
Oct, 2030

(7 years from now)

US10086080 JOURNEY Topical tetracycline compositions
Oct, 2030

(7 years from now)

US8992896 JOURNEY Topical tetracycline compositions
Oct, 2030

(7 years from now)

US10137200 JOURNEY Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
Oct, 2030

(7 years from now)

US9675700 JOURNEY Topical tetracycline compositions
Oct, 2030

(7 years from now)

US8865139 JOURNEY Topical tetracycline compositions
Oct, 2030

(7 years from now)

Drugs and Companies using MINOCYCLINE HYDROCHLORIDE ingredient

Market Authorisation Date: 18 October, 2019

Treatment: Treatment of non-nodular acne vulgaris

Dosage: AEROSOL, FOAM;TOPICAL

How can I launch a generic of AMZEEQ before it's patent expiration?
More Information on Dosage

9. List of Anjeso drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11253478 BAUDAX Reduction of flake-like aggregation in nanoparticulate active agent compositions
May, 2030

(7 years from now)

US9974746 BAUDAX Reduction of flake-like aggregation in nanoparticulate active agent compositions
May, 2030

(7 years from now)

US10709713 BAUDAX Nanoparticulate meloxicam formulations
May, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Feb 20, 2023

Drugs and Companies using MELOXICAM ingredient

Market Authorisation Date: 20 February, 2020

Treatment: Management of moderate-to-severe pain by injection; Management of moderate-to-severe pain by intravenous injection

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

10. List of Anoro Ellipta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser
Mar, 2030

(7 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser
Oct, 2030

(7 years from now)

US9750726 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Nov, 2030

(7 years from now)

US11090294 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
M Jun 9, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 18 December, 2013

Treatment: Maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: POWDER;INHALATION

More Information on Dosage

11. List of Apadaz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9132125 KVK TECH INC Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Jul, 2030

(7 years from now)

US9549923 KVK TECH INC Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and uses thereof
Jul, 2030

(7 years from now)

US8748413 KVK TECH INC Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Jul, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8828978 KVK TECH INC Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
Jul, 2030

(7 years from now)

Drugs and Companies using ACETAMINOPHEN; BENZHYDROCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 February, 2018

Treatment: Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate

Dosage: TABLET;ORAL

More Information on Dosage

12. List of Apriso drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8865688 VALEANT PHARMS INTL Compositions and methods for treatment of bowel diseases with granulated mesalamine
May, 2030

(7 years from now)

Drugs and Companies using MESALAMINE ingredient

Market Authorisation Date: 31 October, 2008

Treatment: For the maintenance of remission of ulcerative colitis

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of APRISO before it's patent expiration?
More Information on Dosage

13. List of Aptiom drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8372431 SUNOVION PHARMS INC Pharmaceutical composition comprising licarbazepine acetate
Apr, 2030

(7 years from now)

Drugs and Companies using ESLICARBAZEPINE ACETATE ingredient

Market Authorisation Date: 08 November, 2013

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of APTIOM before it's patent expiration?
More Information on Dosage

14. List of Aristada drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112903 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

US8431576 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Oct, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796276 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 05 October, 2015

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

15. List of Aristada Initio Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10112903 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

US8431576 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Oct, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796276 ALKERMES INC Heterocyclic compounds for the treatment of neurological and psychological disorders
Jun, 2030

(7 years from now)

Drugs and Companies using ARIPIPRAZOLE LAUROXIL ingredient

Market Authorisation Date: 29 June, 2018

Treatment: Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

16. List of Arnuity Ellipta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser
Mar, 2030

(7 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser
Oct, 2030

(7 years from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 20 August, 2014

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

17. List of Atrovent Hfa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8474447 BOEHRINGER INGELHEIM Inhaler device
Jan, 2030

(6 years from now)

Drugs and Companies using IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 27 November, 2004

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

18. List of Aubagio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802735 SANOFI AVENTIS US (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
Sep, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
M Apr 30, 2024
Pediatric Exclusivity (PED) Oct 30, 2024

Drugs and Companies using TERIFLUNOMIDE ingredient

Market Authorisation Date: 12 September, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of AUBAGIO before it's patent expiration?
More Information on Dosage

19. List of Auryxia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9387191 KERYX BIOPHARMS Ferric citrate dosage forms
Jul, 2030

(7 years from now)

US10300039 KERYX BIOPHARMS Ferric citrate dosage forms
Jul, 2030

(7 years from now)

Drugs and Companies using FERRIC CITRATE ingredient

Market Authorisation Date: 05 September, 2014

Treatment: Control of serum phosphorus levels

Dosage: TABLET;ORAL

More Information on Dosage

20. List of Avycaz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8835455 ALLERGAN Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt
Oct, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 25, 2020
Generating Antibiotic Incentives Now (GAIN) Feb 25, 2025

Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 25 February, 2015

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

21. List of Besivance drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8604020 BAUSCH AND LOMB Fluoroquinolone carboxylic acid molecular crystals
Mar, 2030

(7 years from now)

US8415342 BAUSCH AND LOMB Besifloxacin ophthalmic composition for the treatment or control of infection
Nov, 2030

(7 years from now)

Drugs and Companies using BESIFLOXACIN HYDROCHLORIDE ingredient

Market Authorisation Date: 28 May, 2009

Treatment: Method of treating ocular bacterial infections

Dosage: SUSPENSION/DROPS;OPHTHALMIC

More Information on Dosage

22. List of Bevespi Aerosphere drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8324266 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(7 years from now)

US10716753 ASTRAZENECA Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
May, 2030

(7 years from now)

US9415009 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(7 years from now)

US8703806 ASTRAZENECA Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents
May, 2030

(7 years from now)

US8808713 ASTRAZENECA Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems
May, 2030

(7 years from now)

US9463161 ASTRAZENECA Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
May, 2030

(7 years from now)

Drugs and Companies using FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

23. List of Bevyxxa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8987463 PORTOLA PHARMS INC Methods of synthesizing factor Xa inhibitors
Dec, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 23, 2022

Drugs and Companies using BETRIXABAN ingredient

NCE-1 date: June, 2021

Market Authorisation Date: 23 June, 2017

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

24. List of Beyaz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8617597 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid
Feb, 2030

(7 years from now)

Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient

Market Authorisation Date: 24 September, 2010

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of BEYAZ before it's patent expiration?
More Information on Dosage

25. List of Braftovi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8541575 ARRAY BIOPHARMA INC 3,4-diarylpyrazoles as protein kinase inhibitors
Feb, 2030

(7 years from now)

US9593099 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9850229 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US9593100 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US9850230 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US10005761 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 27, 2023
Orphan Drug Exclusivity (ODE) Jun 27, 2025
New Indication (I) Apr 8, 2023

Drugs and Companies using ENCORAFENIB ingredient

NCE-1 date: June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Indicated in combination with binimetinib for the treatment of melanoma with a braf mutation; Treatment of melanoma with a braf mutation; Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; Braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test; Treatment of melanoma

Dosage: CAPSULE;ORAL

How can I launch a generic of BRAFTOVI before it's patent expiration?
More Information on Dosage

26. List of Breo Ellipta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281 GLAXO GRP LTD Manifold for use in medicament dispenser
Mar, 2030

(7 years from now)

US8746242 GLAXO GRP LTD Medicament dispenser
Oct, 2030

(7 years from now)

Drugs and Companies using FLUTICASONE FUROATE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 10 May, 2013

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

27. List of Brexafemme drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8188085 SCYNEXIS Antifungal agents
Aug, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 1, 2026
Generating Antibiotic Incentives Now (GAIN) Jun 1, 2031

Drugs and Companies using IBREXAFUNGERP CITRATE ingredient

NCE-1 date: June, 2030

Market Authorisation Date: 01 June, 2021

Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc)

Dosage: TABLET;ORAL

More Information on Dosage

28. List of Breztri Aerosphere drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9463161 ASTRAZENECA AB Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
May, 2030

(7 years from now)

US8703806 ASTRAZENECA AB Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents
May, 2030

(7 years from now)

US8808713 ASTRAZENECA AB Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems
May, 2030

(7 years from now)

US8324266 ASTRAZENECA AB Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(7 years from now)

US9415009 ASTRAZENECA AB Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(7 years from now)

US10716753 ASTRAZENECA AB Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
May, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Combination (NC) Jul 23, 2023

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 23 July, 2020

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

29. List of Brilinta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8425934 ASTRAZENECA Pharmaceutical compositions
Apr, 2030

(7 years from now)

US8425934

(Pediatric)

ASTRAZENECA Pharmaceutical compositions
Oct, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Nov 5, 2023
M May 9, 2025
Pediatric Exclusivity (PED) Nov 28, 2023

Drugs and Companies using TICAGRELOR ingredient

Market Authorisation Date: 20 July, 2011

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of BRILINTA before it's patent expiration?
More Information on Dosage

30. List of Briviact drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10729653 UCB INC Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
Apr, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Aug 27, 2024

Drugs and Companies using BRIVARACETAM ingredient

Market Authorisation Date: 12 May, 2016

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of BRIVIACT before it's patent expiration?
More Information on Dosage

31. List of Bydureon drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8998876 ASTRAZENECA AB Ampoule comprising an ampoule holder
Jan, 2030

(6 years from now)

US8721615 ASTRAZENECA AB Ampoule comprising an ampoule holder
Jan, 2030

(6 years from now)

US8998876

(Pediatric)

ASTRAZENECA AB Ampoule comprising an ampoule holder
Jul, 2030

(7 years from now)

US8721615

(Pediatric)

ASTRAZENECA AB Ampoule comprising an ampoule holder
Jul, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 22, 2024
M Feb 15, 2022
Pediatric Exclusivity (PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 27 January, 2012

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

32. List of Bydureon Bcise drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8895033 ASTRAZENECA AB Sustained release formulations using non-aqueous carriers
Oct, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Jul 22, 2024
M Feb 15, 2022
Pediatric Exclusivity (PED) Jan 22, 2025

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Market Authorisation Date: 20 October, 2017

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; Stimulating insulin release in adults with type 2 diabetes mellitus by administering a pre-mixed exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; Delaying gastric emptying in adults with type 2 diabetes mellitus by administering a pre-mixed exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; Improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage

33. List of Cabometyx drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11091439 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
Jan, 2030

(6 years from now)

US8877776 EXELIXIS INC (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Oct, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11098015 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
Jan, 2030

(6 years from now)

US11091440 EXELIXIS INC Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer
Jan, 2030

(6 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 17, 2028
New Indication (I) Sep 17, 2024

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Treatment of patients with hepatocellular carcinoma (hcc) who have been previously treated with sorafenib; Treatment of renal cell carcinoma; Treatment of advanced renal cell carcinoma; Treatment of differentiated thyroid cancer that has progressed following prior vegfr-targeted therapy

Dosage: TABLET;ORAL

How can I launch a generic of CABOMETYX before it's patent expiration?
More Information on Dosage

34. List of Caldolor drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9012508 CUMBERLAND PHARMS Administration of intravenous ibuprofen
Sep, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
M Nov 19, 2024

Drugs and Companies using IBUPROFEN ingredient

Market Authorisation Date: 11 June, 2009

Treatment: Management of mild to moderate pain, management of moderate to severe pain as an adjunct to opioid analgesics, reduction in fever through anti-inflammatory, analgesic, and antipyretic activity

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

35. List of Cerdelga drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11458119 GENZYME CORP Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
Nov, 2030

(7 years from now)

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

Market Authorisation Date: 19 August, 2014

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of CERDELGA before it's patent expiration?
More Information on Dosage

36. List of Children's Allegra Allergy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8933097 CHATTEM SANOFI Fexofenadine suspension formulation
Aug, 2030

(7 years from now)

Drugs and Companies using FEXOFENADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 January, 2011

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

37. List of Combivent Respimat drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8733341 BOEHRINGER INGELHEIM Atomizer and method of atomizing fluid with a nozzle rinsing mechanism
Oct, 2030

(7 years from now)

Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: NA

Dosage: SPRAY, METERED;INHALATION

More Information on Dosage

38. List of Cometriq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11091439 EXELIXIS Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
Jan, 2030

(6 years from now)

US8877776 EXELIXIS (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
Oct, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11091440 EXELIXIS Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)- N′-(4-fluorophenyl)cyclopropane-1,1 -dicarboxamide, and crystalline forms thereof for the treatment of cancer
Jan, 2030

(6 years from now)

US11098015 EXELIXIS Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
Jan, 2030

(6 years from now)

Drugs and Companies using CABOZANTINIB S-MALATE ingredient

Market Authorisation Date: 29 November, 2012

Treatment: Method of treating medullary thyroid cancer

Dosage: CAPSULE;ORAL

More Information on Dosage

39. List of Consensi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9408837 PURPLE BIOTECH Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
Feb, 2030

(7 years from now)

Drugs and Companies using AMLODIPINE BESYLATE; CELECOXIB ingredient

Market Authorisation Date: 31 May, 2018

Treatment: Treatment of adult patients for whom treatment with both amlodipine for hypertension and celecoxib for osteoarthritis are appropriate

Dosage: TABLET;ORAL

How can I launch a generic of CONSENSI before it's patent expiration?
More Information on Dosage

40. List of Contrave drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8916195 NALPROPION Sustained release formulation of naltrexone
Feb, 2030

(7 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 10 September, 2014

Treatment: Use of naltrexone and bupropion in extended-release form for chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of CONTRAVE before it's patent expiration?
More Information on Dosage

41. List of Copiktra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8193182 SECURA Substituted isoquinolin-1(2H)-ones, and methods of use thereof
Feb, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 24, 2023
Orphan Drug Exclusivity (ODE) Sep 24, 2025

Drugs and Companies using DUVELISIB ingredient

NCE-1 date: September, 2022

Market Authorisation Date: 24 September, 2018

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

42. List of Cotellic drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803839

(Pediatric)

GENENTECH INC Azetidines as MEK inhibitors for the treatment of proliferative diseases
May, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 10, 2022
New Indication (I) Oct 28, 2025
M Jul 28, 2025
Pediatric Exclusivity (PED) Jan 28, 2026

Drugs and Companies using COBIMETINIB FUMARATE ingredient

Market Authorisation Date: 10 November, 2015

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

43. List of Cubicin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9138456 CUBIST PHARMS LLC Lipopeptide compositions and related methods
Nov, 2030

(7 years from now)

Drugs and Companies using DAPTOMYCIN ingredient

Market Authorisation Date: 12 September, 2003

Treatment: NA

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of CUBICIN before it's patent expiration?
More Information on Dosage

44. List of Cycloset drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8877708 VEROSCIENCE Combination of dopamine agonists plus first phase secretagogues for the treatment of metabolic disorders
Jun, 2030

(7 years from now)

US10688155 VEROSCIENCE Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
Jun, 2030

(7 years from now)

US9352025 VEROSCIENCE Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
Jun, 2030

(7 years from now)

US9895422 VEROSCIENCE Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
Jun, 2030

(7 years from now)

Drugs and Companies using BROMOCRIPTINE MESYLATE ingredient

Market Authorisation Date: 05 May, 2009

Treatment: Treatment of type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue wherein the combined therapeutic effect is greater than the additive effect of administering each agent alone; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claims 1 and 10; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 19 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 16 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 2 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 30 wherein the effects are as recited in claim 26; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 27 and wherein the effects are as recited in claim 26; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 17 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 15 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 28 and wherein the effects are as recited in claim 26; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine meylate and a first-phase insulin secretagogue as recited in claims 1 and 3 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 8 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 5 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claims 1 and 11; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1, 17 and 18 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claims 1 and 13; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 22 wherein the effects are as recited in claim 22; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 22 and 24 and wherein the effects are as recited in claim 22; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 29 and wherein the effects are as recited in claim 26; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 6 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 26 and wherein the effects are as recited in claim 26; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 4 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1 and 7 and wherein the effects are as recited in claim 1; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 22 and 25 and wherein the effects are as recited in claim 22; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 1 and wherein the effects are as recited in claims 1 and 9; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 22 and 23 and wherein the effects are as recited in claim 22; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 56 and wherein the effects are as recited in claim 44; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 31 and wherein the effects are as recited in claim 26; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 44 and wherein the effects are as recited in claims 44 and 54; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 50 wherein the effects are as recited in said claims; Adjunct to diet and exercise to treat glucose intolerance in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 42 and wherein the effects are as recited in claim 42; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 44 and wherein the effects are as recited in claim 44; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 49 and wherein the effects are as recited in claim 44; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 45 and wherein the effects are as recited in claim 44; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 34 wherein the effects are as recited in said claims; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 51 wherein the effects are as recited in said claims; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 32 wherein the effects are as recited in said claims; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 38 and wherein the effects are as recited claim 26; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 39 and wherein the effects are as recited in claim 26; Once daily topical treatment of persistent facial erythema associated with rosacea in adults; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 36 wherein the effects are as recited in said claims; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 48 and wherein the effects are as recited in claim 44; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 33 wherein the effects are as recited in claims; Adjunct to diet and exercise to treat glucose intolerance in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 42 and 43 wherein the effects are as recited in claim 42; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 47 and wherein the effects are as recited in claim 44; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 26 and 40 and wherein the effects are as recited in claim 26; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 57 and wherein the effects are as recited in claim 44; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 46 and wherein the effects are as recited in claim 44; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 44 and 52 wherein the effects are as recited in said claims; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 1-5 and wherein the effects are as recited in claims 1-5; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 7 and wherein the effects are as recited in claim 7; Adjunct to diet and exercise to treat glucose intolerance in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 14-15 and wherein the effects are as recited in claims 14-15; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 9 and wherein the effects are as recited in claim 9; Adjunct to diet and exercise to treat glucose intolerance in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 16-18 and wherein the effects are as recited in claims 16-18; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 10 and wherein the effects are as recited in claim 10; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 6 and wherein the effects are as recited in claim 6; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 19 and wherein the effects are as recited in claim 19; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 12 and wherein the effects are as recited in claim 12; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 11 and wherein the effects are as recited in claim 11; Adjunct to diet and exercise to treat glucose intolerance in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 2 and wherein the effects are as recited in claim 2; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 16-19 and wherein the effects are as recited in claims 16-19; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 8 and wherein the effects are as recited in claim 8; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claim 14 and wherein the effects are as recited in claim 14; Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes by administering bromocriptine mesylate and a first-phase insulin secretagogue as recited in claims 3-7 and wherein the effects are as recited in claims 3-7

Dosage: TABLET;ORAL

More Information on Dosage

45. List of Dexilant drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173158 TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food
Mar, 2030

(7 years from now)

US8173158

(Pediatric)

TAKEDA PHARMS USA Methods of treating gastrointestinal disorders independent of the intake of food
Sep, 2030

(7 years from now)

Drugs and Companies using DEXLANSOPRAZOLE ingredient

Market Authorisation Date: 30 January, 2009

Treatment: Treatment of heartburn associated with non-erosive gastroesophageal reflux disease (gerd) for 4 weeks; Healing of all grades of erosive esophagitis (ee) for up to 8 weeks; Maintain healing of erosive esophagitis (ee) for up to 6 months

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of DEXILANT before it's patent expiration?
More Information on Dosage

46. List of Dextenza drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8563027 OCULAR THERAPEUTIX Drug delivery through hydrogel plugs
Feb, 2030

(7 years from now)

US8409606 OCULAR THERAPEUTIX Drug delivery through hydrogel plugs
May, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Oct 7, 2024

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 30 November, 2018

Treatment: Dextenza is approved for the treatment of ocular pain following ophthalmic surgery

Dosage: INSERT;OPHTHALMIC

More Information on Dosage

47. List of Dsuvia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8574189 ACELRX PHARMS Storage and dispensing devices for administration of oral transmucosal dosage forms
Mar, 2030

(7 years from now)

US10896751 ACELRX PHARMS Storage and dispensing devices for administration of oral transmucosal dosage forms
Mar, 2030

(7 years from now)

US8865743 ACELRX PHARMS Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
Oct, 2030

(7 years from now)

US8202535 ACELRX PHARMS Small-volume oral transmucosal dosage forms
Oct, 2030

(7 years from now)

Drugs and Companies using SUFENTANIL CITRATE ingredient

Market Authorisation Date: 02 November, 2018

Treatment: Treatment of acute pain

Dosage: TABLET;SUBLINGUAL

More Information on Dosage

48. List of Edarbyclor drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9169238 AZURITY Solid pharmaceutical composition
Feb, 2030

(7 years from now)

Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient

Market Authorisation Date: 20 December, 2011

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of EDARBYCLOR before it's patent expiration?
More Information on Dosage

49. List of Ella drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10772897 LAB HRA PHARMA Method for on-demand contraception
Apr, 2030

(7 years from now)

US10159681 LAB HRA PHARMA Method for on-demand contraception
Apr, 2030

(7 years from now)

US9283233 LAB HRA PHARMA Method for on-demand contraception
Apr, 2030

(7 years from now)

US8512745 LAB HRA PHARMA Ulipristal acetate tablets
Jun, 2030

(7 years from now)

US8962603 LAB HRA PHARMA Method for post coital contraception in overweight or obese female subjects using ulipristal acetate
Jun, 2030

(7 years from now)

US8426392 LAB HRA PHARMA Method for providing emergency contraception
Jun, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
M Jun 24, 2024

Drugs and Companies using ULIPRISTAL ACETATE ingredient

Market Authorisation Date: 13 August, 2010

Treatment: A method for contraception, the method comprising administering a tablet comprising 20 mg to 30 mg of ulipristal acetate to a woman within 120 hours after an unprotected intercourse; A method for contraception comprising the step of oral administration a dosage of 20 mg to 30 mg of ulipristal acetate to a woman within 72 hours and up to 120 hours after an unprotected intercourse; Method for contraception to a woman comprising administering to the woman 30mg of ulipristal acetate more than 72 hours and up to 120 hours after an unprotected intercourse; Method for providing post coital contraception to a woman by administering about 30 mg of ulipristal acetate within about 120 hours after intercourse, wherein the woman is overweight having a bmi of 25 to 29.99; Ella is a progesterone agonist/antagonist emergency contraception indicated for the prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. ella can be taken with or without food

Dosage: TABLET;ORAL

How can I launch a generic of ELLA before it's patent expiration?
More Information on Dosage

50. List of Entereg drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8946262 CUBIST PHARMS Methods of preventing and treating gastrointestinal dysfunction
Feb, 2030

(7 years from now)

Drugs and Companies using ALVIMOPAN ingredient

Market Authorisation Date: 20 May, 2008

Treatment: A method to accelerate the time to gastrointestinal recovery by administering about 12 mg of alvimopan to the patient from about 30 to 60 minutes prior to surgery

Dosage: CAPSULE;ORAL

How can I launch a generic of ENTEREG before it's patent expiration?
More Information on Dosage

51. List of Epclusa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(7 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 10, 2028
New Strength (NS) Mar 19, 2023
M Apr 27, 2025
New Dosing Schedule (D) Nov 15, 2022
New Patient Population (NPP) Mar 19, 2023
Pediatric Exclusivity (PED) May 15, 2023

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Market Authorisation Date: 28 June, 2016

Treatment: For the treatment of hepatitis c

Dosage: TABLET;ORAL

More Information on Dosage

52. List of Erleada drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8445507 JANSSEN BIOTECH Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Sep, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 14, 2023
New Indication (I) Sep 17, 2022

Drugs and Companies using APALUTAMIDE ingredient

NCE-1 date: February, 2022

Market Authorisation Date: 14 February, 2018

Treatment: Treatment of metastatic castration-sensitive prostate cancer (mcspc); Treatment of non-metastatic, castration-resistant prostate cancer (nm-crpc)

Dosage: TABLET;ORAL

How can I launch a generic of ERLEADA before it's patent expiration?
More Information on Dosage

53. List of Esbriet drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7816383 GENENTECH INC Methods of administering pirfenidone therapy
Jan, 2030

(6 years from now)

US8318780 GENENTECH INC Methods of administering pirfenidone therapy
Jan, 2030

(6 years from now)

US7910610 GENENTECH INC Methods of administering pirfenidone therapy
Jan, 2030

(6 years from now)

US8754109 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450
Jan, 2030

(6 years from now)

US8084475 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450
Jan, 2030

(6 years from now)

US8648098 GENENTECH INC Pirfenidone therapy and inducers of cytochrome P450
Jan, 2030

(6 years from now)

US8013002 GENENTECH INC Methods of administering pirfenidone therapy
Jan, 2030

(6 years from now)

Drugs and Companies using PIRFENIDONE ingredient

Market Authorisation Date: 11 January, 2017

Treatment: Method for administering pirfenidone to reduce drug interactions with fluvoxamine; Method for administering pirfenidone while avoiding or discontinuing concomitant use of a moderate to strong inhibitor of both cyp1a2 and another cyp enzyme involved in pirfenidone metabolism; Administering pirfenidone while avoiding co-administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone; Discontinuing administration of a strong cyp1a2 inhibitor to avoid drug interactions with pirfenidone and then administering pirfenidone; Method for administering pirfenidone to avoid reduced efficacy by avoiding smoking or by avoiding another strong cyp1a2 inducer; Method for administering pirfenidone to avoid reduced efficacy by discontinuing smoking or by discontinuing or avoiding another strong cyp1a2 inducer; Discontinuing smoking to avoid reduced pirfenidone efficacy and then administering pirfenidone; Discontinuing administration of a strong cyp1a2 inducer to avoid reduced pirfenidone efficacy and then administering pirfenidone

Dosage: TABLET;ORAL

How can I launch a generic of ESBRIET before it's patent expiration?
More Information on Dosage

54. List of Eucrisa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168614 ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Jan, 2030

(6 years from now)

US8168614

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Jul, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Mar 23, 2023
Pediatric Exclusivity (PED) Jun 14, 2022

Drugs and Companies using CRISABOROLE ingredient

Market Authorisation Date: 14 December, 2016

Treatment: Method of treating mild to moderate atopic dermatitis.

Dosage: OINTMENT;TOPICAL

How can I launch a generic of EUCRISA before it's patent expiration?
More Information on Dosage

55. List of Evomela drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11020363 ACROTECH Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
May, 2030

(7 years from now)

US10864183 ACROTECH Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
May, 2030

(7 years from now)

US10940128 ACROTECH Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
Jun, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Mar 10, 2023

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 10 March, 2016

Treatment: For high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of EVOMELA before it's patent expiration?
More Information on Dosage

56. List of Exem Foam Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9034300 GISKIT Composition and method for medical imaging of body cavities
Oct, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 7, 2024

Drugs and Companies using AIR POLYMER-TYPE A ingredient

NCE-1 date: November, 2023

Market Authorisation Date: 07 November, 2019

Treatment: Use in sonohysterosalpinography to assess fallopian tube patency

Dosage: FOAM;INTRAUTERINE

More Information on Dosage

57. List of Fabior drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10568859 MAYNE PHARMA Topical foam composition
Feb, 2030

(7 years from now)

US10688071 MAYNE PHARMA Topical foam composition
Feb, 2030

(7 years from now)

US8808716 MAYNE PHARMA Topical foam composition
Feb, 2030

(7 years from now)

Drugs and Companies using TAZAROTENE ingredient

Market Authorisation Date: 11 May, 2012

Treatment: Topical treatment of acne vulgaris in patients 12 years of age or older

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage

58. List of Fanapt drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9157121 VANDA PHARMS INC Method of treatment based on polymorphisms of the KCNQ1 gene
Apr, 2030

(7 years from now)

US8652776 VANDA PHARMS INC Prediction of QT prolongation based on SNP genotype
Aug, 2030

(7 years from now)

US8999638 VANDA PHARMS INC Method of treatment based on polymorphisms of the KCNQ1 gene
Oct, 2030

(7 years from now)

US9074255 VANDA PHARMS INC Method of predicting a predisposition to QT prolongation
Dec, 2030

(7 years from now)

Drugs and Companies using ILOPERIDONE ingredient

Market Authorisation Date: 06 May, 2009

Treatment: Dosage modification to reduce risks associated with qt prolongation not induced by other drugs during treatment with iloperidone; Dosage modification to reduce the risk associated with qt prolongation not induced by other drugs during treatment with iloperidone

Dosage: TABLET;ORAL

How can I launch a generic of FANAPT before it's patent expiration?
More Information on Dosage

59. List of Farxiga drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8721615 ASTRAZENECA AB Ampoule comprising an ampoule holder
Jan, 2030

(6 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
M Feb 22, 2022
New Indication (I) Oct 18, 2022

Drugs and Companies using DAPAGLIFLOZIN ingredient

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone

Dosage: TABLET;ORAL

How can I launch a generic of FARXIGA before it's patent expiration?
More Information on Dosage

60. List of Flolipid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9597289 TCG FLUENT PHARMA Liquid oral simvastatin compositions
Feb, 2030

(7 years from now)

Drugs and Companies using SIMVASTATIN ingredient

Market Authorisation Date: 21 April, 2016

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

61. List of Fosrenol drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9023397 TAKEDA PHARMS USA Capsule and powder formulations containing lanthanum compounds
Dec, 2030

(7 years from now)

US8980327 TAKEDA PHARMS USA Capsule and powder formulations containing lanthanum compounds
Dec, 2030

(7 years from now)

Drugs and Companies using LANTHANUM CARBONATE ingredient

Market Authorisation Date: 24 September, 2014

Treatment: NA

Dosage: POWDER;ORAL

How can I launch a generic of FOSRENOL before it's patent expiration?
More Information on Dosage

62. List of Fyarro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10206887 AADI Prion free nanoparticle compositions and methods of making thereof
Apr, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Nov 22, 2024

Drugs and Companies using SIROLIMUS ingredient

Market Authorisation Date: 22 November, 2021

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

63. List of Gemtesa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8247415 UROVANT Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists
Dec, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 23, 2025

Drugs and Companies using VIBEGRON ingredient

NCE-1 date: December, 2024

Market Authorisation Date: 23 December, 2020

Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency

Dosage: TABLET;ORAL

More Information on Dosage

64. List of Genosyl drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103669 VERO BIOTECH Nitric oxide therapies
Jun, 2030

(7 years from now)

US8607785 VERO BIOTECH Systems and devices for generating nitric oxide
Jul, 2030

(7 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Market Authorisation Date: 20 December, 2019

Treatment: NA

Dosage: GAS;INHALATION

More Information on Dosage

65. List of Genvoya drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9891239

(Pediatric)

GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Mar, 2030

(7 years from now)

US8148374

(Pediatric)

GILEAD SCIENCES INC Modulators of pharmacokinetic properties of therapeutics
Mar, 2030

(7 years from now)

US8633219 GILEAD SCIENCES INC Combination therapy
Apr, 2030

(7 years from now)

US8633219

(Pediatric)

GILEAD SCIENCES INC Combination therapy
Oct, 2030

(7 years from now)

Drugs and Companies using COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE ingredient

Market Authorisation Date: 05 November, 2015

Treatment: Treatment of hiv infection

Dosage: TABLET;ORAL

More Information on Dosage

66. List of Gilotrif drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8426586

(Pediatric)

BOEHRINGER INGELHEIM Process for preparing amino crotonyl compounds
Apr, 2030

(7 years from now)

US8545884

(Pediatric)

BOEHRINGER INGELHEIM Solid pharmaceutical formulations comprising BIBW 2992
Jun, 2030

(7 years from now)

US10004743 BOEHRINGER INGELHEIM Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
Jul, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jan 12, 2025
M Apr 7, 2025
Pediatric Exclusivity (PED) Oct 15, 2023

Drugs and Companies using AFATINIB DIMALEATE ingredient

Market Authorisation Date: 12 July, 2013

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of GILOTRIF before it's patent expiration?
More Information on Dosage

67. List of Gimoti drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8334281 EVOKE PHARMA INC Nasal formulations of metoclopramide
May, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Jun 19, 2023

Drugs and Companies using METOCLOPRAMIDE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 June, 2020

Treatment: Nasal administration of metoclopramide for treatment of diabetic gastroparesis

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of GIMOTI before it's patent expiration?
More Information on Dosage

68. List of Gocovri drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9877933 ADAMAS PHARMA Method of administering amantadine prior to a sleep period
Dec, 2030

(7 years from now)

US8741343 ADAMAS PHARMA Method of administering amantadine prior to a sleep period
Dec, 2030

(7 years from now)

US11197835 ADAMAS PHARMA Method of administering amantadine prior to a sleep period
Dec, 2030

(7 years from now)

US9867792 ADAMAS PHARMA Method of administering amantadine prior to a sleep period
Dec, 2030

(7 years from now)

US9867791 ADAMAS PHARMA Method of administering amantadine prior to a sleep period
Dec, 2030

(7 years from now)

US9867793 ADAMAS PHARMA Method of administering amantadine prior to a sleep period
Dec, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 24, 2024

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 August, 2017

Treatment: Treatment of dyskinesia and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

How can I launch a generic of GOCOVRI before it's patent expiration?
More Information on Dosage

69. List of Harvoni drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8822430 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US8088368 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(7 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8273341 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US8841278 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US9511056 GILEAD SCIENCES INC Antiviral compounds
May, 2030

(7 years from now)

US8088368

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US9511056

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US8822430

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US8841278

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

US8273341

(Pediatric)

GILEAD SCIENCES INC Antiviral compounds
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Dosing Schedule (D) Nov 15, 2022
Orphan Drug Exclusivity (ODE) Apr 7, 2024
Pediatric Exclusivity (PED) Oct 7, 2024

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Market Authorisation Date: 10 October, 2014

Treatment: For the treatment of hepatitis c

Dosage: TABLET;ORAL

More Information on Dosage

70. List of Ibsrela drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9006281 ARDELYX INC Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
May, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Sep 12, 2024

Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient

NCE-1 date: September, 2023

Market Authorisation Date: 12 September, 2019

Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor

Dosage: TABLET;ORAL

More Information on Dosage

71. List of Idhifa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610125 CELGENE CORP Methods and compositions for cell-proliferation-related disorders
Jun, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 1, 2024
New Chemical Entity Exclusivity (NCE) Aug 1, 2022

Drugs and Companies using ENASIDENIB MESYLATE ingredient

NCE-1 date: August, 2021

Market Authorisation Date: 01 August, 2017

Treatment: Treatment of relapsed or refractory acute myeloid leukemia (aml) with an isocitrate dehydrogenase-2 (idh2) mutation

Dosage: TABLET;ORAL

More Information on Dosage

72. List of Ilevro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9662398 NOVARTIS Carboxylvinyl polymer-containing nanoparticle suspensions
Dec, 2030

(7 years from now)

Drugs and Companies using NEPAFENAC ingredient

Market Authorisation Date: 16 October, 2012

Treatment: NA

Dosage: SUSPENSION/DROPS;OPHTHALMIC

How can I launch a generic of ILEVRO before it's patent expiration?
More Information on Dosage

73. List of Implanon drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9757552 ORGANON Applicator for inserting an implant
Jul, 2030

(7 years from now)

Drugs and Companies using ETONOGESTREL ingredient

Market Authorisation Date: 17 July, 2006

Treatment: Prevention of pregnancy

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage

74. List of Impoyz drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9956231 PRIMUS PHARMS Topical formulations comprising a steroid
Aug, 2030

(7 years from now)

US10064875 PRIMUS PHARMS Topical formulations comprising a steroid
Aug, 2030

(7 years from now)

US10588914 PRIMUS PHARMS Topical formulations comprising a steroid
Aug, 2030

(7 years from now)

Drugs and Companies using CLOBETASOL PROPIONATE ingredient

Market Authorisation Date: 28 November, 2017

Treatment: Treatment of moderate plaque psoriasis; Treatment of plaque psoriasis in patients 18 years of age or older; Psoriasis; Twice daily topical treatment of moderate to severe plaque psoriasis.; Treatment of plaque psoriasis; Plaque psoriasis; Treatment of moderate to severe plaque psoriasis in patients 18 years of age or older

Dosage: CREAM;TOPICAL

How can I launch a generic of IMPOYZ before it's patent expiration?
More Information on Dosage

75. List of Incruse Ellipta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8534281 GLAXO GRP ENGLAND Manifold for use in medicament dispenser
Mar, 2030

(7 years from now)

US8746242 GLAXO GRP ENGLAND Medicament dispenser
Oct, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
M Jun 9, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE ingredient

Market Authorisation Date: 30 April, 2014

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

76. List of Inlyta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8791140 PF PRISM CV Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals
Dec, 2030

(7 years from now)

Drugs and Companies using AXITINIB ingredient

Market Authorisation Date: 27 January, 2012

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of INLYTA before it's patent expiration?
More Information on Dosage

77. List of Inqovi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8268800 OTSUKA Certain compounds, compositions and methods
Aug, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 7, 2025
Orphan Drug Exclusivity (ODE) Jul 7, 2027

Drugs and Companies using CEDAZURIDINE; DECITABINE ingredient

NCE-1 date: July, 2024

Market Authorisation Date: 07 July, 2020

Treatment: Treatment of chronic myelomonocytic leukemia; Treatment of myelodysplastic syndrome; Method for inhibiting cytidine deaminase by administering cedazuridine; Method for inhibiting degradation of a cda substrate by administering cedazuridine

Dosage: TABLET;ORAL

More Information on Dosage

78. List of Intrarosa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8957054 MILLICENT Pharmaceutical compositions
Jan, 2030

(6 years from now)

Drugs and Companies using PRASTERONE ingredient

Market Authorisation Date: 16 November, 2016

Treatment: Intravaginal prasterone (dehydroepiandrosterone) at a daily dose of 6.5mg for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause

Dosage: INSERT;VAGINAL

More Information on Dosage

79. List of Isentress drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649311 MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor
Oct, 2030

(7 years from now)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 12 October, 2007

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ISENTRESS before it's patent expiration?
More Information on Dosage

80. List of Jatenzo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10617696 CLARUS Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Apr, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11426416 CLARUS Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Apr, 2030

(7 years from now)

US11179403 CLARUS Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Apr, 2030

(7 years from now)

US10543219 CLARUS Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Apr, 2030

(7 years from now)

US8778916 CLARUS Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Apr, 2030

(7 years from now)

US8492369 CLARUS Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
Dec, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 27, 2022

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 27 March, 2019

Treatment: A method of treating testosterone deficiency in men; Method of treating testosterone deficiency

Dosage: CAPSULE;ORAL

More Information on Dosage

81. List of Jentadueto drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9155705 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
May, 2030

(7 years from now)

US8846695 BOEHRINGER INGELHEIM Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy comprising a DPP-IV inhibitor
Jun, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
M Jul 3, 2022

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 30 January, 2012

Treatment: Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin

Dosage: TABLET;ORAL

How can I launch a generic of JENTADUETO before it's patent expiration?
More Information on Dosage

82. List of Jentadueto Xr drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9155705 BOEHRINGER INGELHEIM DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
May, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
M Jul 3, 2022

Drugs and Companies using LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 27 May, 2016

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of JENTADUETO XR before it's patent expiration?
More Information on Dosage

83. List of Jevtana Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8927592 SANOFI AVENTIS US Antitumoral use of cabazitaxel
Oct, 2030

(7 years from now)

US10716777 SANOFI AVENTIS US Antitumoral use of cabazitaxel
Oct, 2030

(7 years from now)

US10583110 SANOFI AVENTIS US Antitumoral use of cabazitaxel
Oct, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
M Dec 18, 2023

Drugs and Companies using CABAZITAXEL ingredient

Market Authorisation Date: 17 June, 2010

Treatment: Increasing survival in mcrpc patients previously treated with docetaxel by administering cabazitaxel in combination with prednisone or prednisolone after a premedication regimen that includes an antihistamine, a corticosteroid, and an h2-antagonist; Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering 20 to 25 mg/m2 cabazitaxel after a premedication regimen that includes an h2-antagonist; Increasing survival in metastatic castration-resistant prostate cancer patients previously treated with docetaxel by administering as a 3 week cycle cabazitaxel after 5 mg dexchlorpheniramine, 8 mg dexamethasone, and an h2-agonist

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of JEVTANA KIT before it's patent expiration?
More Information on Dosage

84. List of Jublia drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9861698 BAUSCH Compositions and methods for treating diseases of the nail
Jul, 2030

(7 years from now)

US8039494 BAUSCH Compositions and methods for treating diseases of the nail
Jul, 2030

(7 years from now)

US10105444 BAUSCH Compositions and methods for treating diseases of the nail
Jul, 2030

(7 years from now)

US8486978 BAUSCH Compositions and methods for treating diseases of the nail
Oct, 2030

(7 years from now)

US9302009 BAUSCH Compositions and methods for treating diseases of the nail
Oct, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Apr 27, 2023

Drugs and Companies using EFINACONAZOLE ingredient

Market Authorisation Date: 06 June, 2014

Treatment: Antimycotic uses, specifically treatment of onychomycosis

Dosage: SOLUTION;TOPICAL

How can I launch a generic of JUBLIA before it's patent expiration?
More Information on Dosage

85. List of Jynarque drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10905694 OTSUKA Pharmaceutical solid preparation comprising benzazepines and production method thereof
Apr, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 23, 2025

Drugs and Companies using TOLVAPTAN ingredient

Market Authorisation Date: 23 April, 2018

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of JYNARQUE before it's patent expiration?
More Information on Dosage

86. List of Kengreal drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9427448 CHIESI Methods of treating, reducing the incidence of, and/or preventing ischemic events
Nov, 2030

(7 years from now)

Drugs and Companies using CANGRELOR ingredient

Market Authorisation Date: 22 June, 2015

Treatment: Method of treating, reducing the incidence of, or preventing an ischemic event in a patient undergoing pci by administering intravenously 30 ug/kg bolus before pci and continuous infusion of 4 ug/kg/min for at least 2 hours or the duration of the pci

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of KENGREAL before it's patent expiration?
More Information on Dosage

87. List of Kimyrsa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9682061 MELINTA THERAP Methods of treating bacterial infections using oritavancin
Apr, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 12, 2024
New Chemical Entity Exclusivity (NCE) Aug 6, 2019
Generating Antibiotic Incentives Now (GAIN) Aug 6, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 12 March, 2021

Treatment: Treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

88. List of Kisqali drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8685980 NOVARTIS Pyrrolopyrimidine compounds and their uses
May, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 13, 2022
New Patient Population (NPP) Dec 10, 2024

Drugs and Companies using RIBOCICLIB SUCCINATE ingredient

NCE-1 date: March, 2021

Market Authorisation Date: 13 March, 2017

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of KISQALI before it's patent expiration?
More Information on Dosage

89. List of Kisqali Femara Co-pack (copackaged) drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8685980 NOVARTIS Pyrrolopyrimidine compounds and their uses
May, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 13, 2022
New Patient Population (NPP) Dec 10, 2024

Drugs and Companies using LETROZOLE; RIBOCICLIB SUCCINATE ingredient

NCE-1 date: March, 2021

Market Authorisation Date: 04 May, 2017

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of KISQALI FEMARA CO-PACK (COPACKAGED) before it's patent expiration?
More Information on Dosage

90. List of Kovanaze drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9308191 ST RENATUS Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
Apr, 2030

(7 years from now)

US8580282 ST RENATUS Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
Apr, 2030

(7 years from now)

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 29 June, 2016

Treatment: Method of anesthetizing at least a portion of the maxillary dental arch

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

91. List of Kybella drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8101593 KYTHERA BIOPHARMS Formulations of deoxycholic acid and salts thereof
Mar, 2030

(7 years from now)

US10500214 KYTHERA BIOPHARMS Formulations of deoxycholic acid and salts thereof
Mar, 2030

(7 years from now)

US8367649 KYTHERA BIOPHARMS Formulations of deoxycholic acid and salts thereof
Mar, 2030

(7 years from now)

US8653058 KYTHERA BIOPHARMS Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
Mar, 2030

(7 years from now)

Drugs and Companies using DEOXYCHOLIC ACID ingredient

Market Authorisation Date: 29 April, 2015

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

How can I launch a generic of KYBELLA before it's patent expiration?
More Information on Dosage

92. List of Kynmobi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9283219 SUNOVION PHARMS INC Sublingual films
Jun, 2030

(7 years from now)

US9669019 SUNOVION PHARMS INC Sublingual apomorphine
Jun, 2030

(7 years from now)

US9669021 SUNOVION PHARMS INC Sublingual apomorphine
Jun, 2030

(7 years from now)

US9326981 SUNOVION PHARMS INC Sublingual apomorphine
Jun, 2030

(7 years from now)

US9044475 SUNOVION PHARMS INC Sublingual apomorphine
Jun, 2030

(7 years from now)

US10420763 SUNOVION PHARMS INC Sublingual apomorphine
Jun, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) May 21, 2023

Drugs and Companies using APOMORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 21 May, 2020

Treatment: Treatment of 'off' episodes in patients with parkinson's disease

Dosage: FILM;SUBLINGUAL

More Information on Dosage

93. List of Kyzatrex drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10576090 MARIUS PHARMS LLC Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
Dec, 2030

(7 years from now)

US10576089 MARIUS PHARMS LLC Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols
Dec, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Jul 27, 2025

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 27 July, 2022

Treatment: Method of treating testosterone deficiency

Dosage: CAPSULE;ORAL

More Information on Dosage

94. List of Lonhala Magnair Kit drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9789270 SUNOVION RESP Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized
Oct, 2030

(7 years from now)

Drugs and Companies using GLYCOPYRROLATE ingredient

Market Authorisation Date: 05 December, 2017

Treatment: NA

Dosage: SOLUTION;INHALATION

More Information on Dosage

95. List of Lumify drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8293742 BAUSCH AND LOMB INC Preferential vasoconstriction compositions and methods of use
Jul, 2030

(7 years from now)

US9259425 BAUSCH AND LOMB INC Compositions and methods for eye whitening
Jul, 2030

(7 years from now)

Drugs and Companies using BRIMONIDINE TARTRATE ingredient

Market Authorisation Date: 22 December, 2017

Treatment: Relieves redness of the eye due to minor eye irritations

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of LUMIFY before it's patent expiration?
More Information on Dosage

96. List of Mavyret drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039754 ABBVIE INC Anti-viral compounds
Jun, 2030

(7 years from now)

US10028937 ABBVIE INC Anti-viral compounds
Jun, 2030

(7 years from now)

US9586978 ABBVIE INC Anti-viral compounds
Nov, 2030

(7 years from now)

US10028937

(Pediatric)

ABBVIE INC Anti-viral compounds
Dec, 2030

(7 years from now)

US10039754

(Pediatric)

ABBVIE INC Anti-viral compounds
Dec, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 3, 2022
M Apr 10, 2023
New Dosing Schedule (D) Sep 26, 2022
Orphan Drug Exclusivity (ODE) Jun 10, 2028
Pediatric Exclusivity (PED) Mar 26, 2023

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

NCE-1 date: March, 2022

Market Authorisation Date: 10 June, 2021

Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg; Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in pediatric patients 3 to less than 12 years of age or weighing less than 45 kg

Dosage: PELLETS;ORAL

More Information on Dosage

97. List of Mayzent drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8492441 NOVARTIS Dosage regimen of an S1P receptor agonist
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Mar 26, 2024
M Mar 1, 2025

Drugs and Companies using SIPONIMOD FUMARIC ACID ingredient

NCE-1 date: March, 2023

Market Authorisation Date: 26 March, 2019

Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose

Dosage: TABLET;ORAL

More Information on Dosage

98. List of Mekinist drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8703781 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
Oct, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8952018 NOVARTIS Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
Oct, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 22, 2024
M Oct 6, 2022
New Indication (I) Jun 22, 2025

Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient

Market Authorisation Date: 29 May, 2013

Treatment: Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with braf v600e mutation as detected by an fda-approved test; Mekinist is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options; Mekinist is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with braf v600e or v600k mutations, as detected by an fda-approved test, and involvement of lymph node(s), following complete resection; Mekinist is indicated, as a single agent or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with braf v600e or v600k mutations, as detected by an fda-approved test; Mekinist in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma

Dosage: TABLET;ORAL

More Information on Dosage

99. List of Mektovi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9850229 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US10005761 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

US9593100 ARRAY BIOPHARMA INC Compounds and compositions as protein kinase inhibitors
Aug, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 27, 2023
Orphan Drug Exclusivity (ODE) Jun 27, 2025

Drugs and Companies using BINIMETINIB ingredient

NCE-1 date: June, 2022

Market Authorisation Date: 27 June, 2018

Treatment: Indicated in combination with encorafenib for the treatment of melanoma with a braf mutation; Indicated in combination with encorafenib for the treatment of melanoma

Dosage: TABLET;ORAL

How can I launch a generic of MEKTOVI before it's patent expiration?
More Information on Dosage

100. List of Milprosa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8580293 FERRING PHARMS INC Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof
Jan, 2030

(6 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Apr 29, 2023

Drugs and Companies using PROGESTERONE ingredient

Market Authorisation Date: 29 April, 2020

Treatment: Method of supporting embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women

Dosage: SYSTEM;VAGINAL

More Information on Dosage

101. List of Minivelle drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8231906 NOVEN Transdermal estrogen device and delivery
Jul, 2030

(7 years from now)

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 29 October, 2012

Treatment: NA

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

How can I launch a generic of MINIVELLE before it's patent expiration?
More Information on Dosage

102. List of Mulpleta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8530668 SHIONOGI INC Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
Jan, 2030

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 31, 2023

Drugs and Companies using LUSUTROMBOPAG ingredient

NCE-1 date: July, 2022

Market Authorisation Date: 31 July, 2018

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

103. List of Myoview drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549999 GE HEALTHCARE Radiopharmaceutical composition
Mar, 2030

(7 years from now)

Drugs and Companies using TECHNETIUM TC-99M TETROFOSMIN KIT ingredient

Market Authorisation Date: 09 February, 1996

Treatment: NA

Dosage: INJECTABLE;INJECTION

More Information on Dosage

104. List of Myrbetriq drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10842780

(Pediatric)

APGDI Pharmaceutical composition for modified release
Mar, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Mar 25, 2024
Pediatric Exclusivity (PED) Sep 25, 2024

Drugs and Companies using MIRABEGRON ingredient

Market Authorisation Date: 28 June, 2012

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of MYRBETRIQ before it's patent expiration?
More Information on Dosage

105. List of Nerlynx drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7399865 PUMA BIOTECH Protein tyrosine kinase enzyme inhibitors
Dec, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9211291 PUMA BIOTECH Treatment regimen utilizing neratinib for breast cancer
Mar, 2030

(7 years from now)

US8790708 PUMA BIOTECH Coated tablet formulations and uses thereof
Nov, 2030

(7 years from now)

US8518446 PUMA BIOTECH Coated tablet formulations and uses thereof
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 17, 2022
New Indication (I) Feb 25, 2023
New Dosing Schedule (D) Jun 28, 2024

Drugs and Companies using NERATINIB MALEATE ingredient

NCE-1 date: July, 2021

Market Authorisation Date: 17 July, 2017

Treatment: Extended adjuvant treatment of adult patients with early stage her2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab base therapy; Extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (her2)-positive breast cancer, to follow adjuvant trastuzumab based therapy; Use in combination with capecitabine, for the treatment of adult patients with advanced or metastatic her2-positive breast cancer who have received two or more prior anti-her2 based regimens in the metastatic setting

Dosage: TABLET;ORAL

How can I launch a generic of NERLYNX before it's patent expiration?
More Information on Dosage

106. List of Neupro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130589 UCB INC Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
Dec, 2030

(7 years from now)

US10350174 UCB INC Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
Dec, 2030

(7 years from now)

Drugs and Companies using ROTIGOTINE ingredient

Market Authorisation Date: 09 May, 2007

Treatment: NA

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

How can I launch a generic of NEUPRO before it's patent expiration?
More Information on Dosage

107. List of Nithiodote drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9345724 HOPE PHARMS Sodium thiosulfate-containing pharmaceutical compositions
Jul, 2030

(7 years from now)

US9585912 HOPE PHARMS Sodium thiosulfate-containing pharmaceutical compositions
Jul, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9687506 HOPE PHARMS Sodium nitrite-containing pharmaceutical compositions
Feb, 2030

(7 years from now)

US10479686 HOPE PHARMS Sodium thiosulfate-containing pharmaceutical compositions
Jul, 2030

(7 years from now)

Drugs and Companies using SODIUM NITRITE; SODIUM THIOSULFATE ingredient

Market Authorisation Date: 14 January, 2011

Treatment: Sodium nitrite injection is administered by intravenous injection; Sodium nitrite injection is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning; Sodium thiosulfate injection is administered by intravenous injection; Sodium thiosulfate injection is indicated for sequential use with sodium nitrite for the treatment of acute cyanide poisoning

Dosage: SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS

More Information on Dosage

108. List of Nocdurna drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9974826 FERRING PHARMS INC Methods comprising desmopressin
Apr, 2030

(7 years from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Market Authorisation Date: 21 June, 2018

Treatment: Treatment of nocturia due to nocturnal polyuria in adults; Treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration

Dosage: TABLET;SUBLINGUAL

More Information on Dosage

109. List of Noctiva drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539302 SERENITY PHARMS LLC Safe desmopressin administration
Jun, 2030

(7 years from now)

US11419914 SERENITY PHARMS LLC Safe desmopressin administration
Jun, 2030

(7 years from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Market Authorisation Date: 03 March, 2017

Treatment: Treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void by inducing an antidiuretic effect by intranasally administering a plume of droplets comprising a dose of about 0.05-5 mcg desmopressin

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

110. List of Nubeqa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9657003 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(7 years from now)

US8975254 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(7 years from now)

US11046713 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(7 years from now)

US10711013 BAYER HEALTHCARE Androgen receptor modulating compounds
Oct, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jul 30, 2024
New Indication (I) Aug 5, 2025

Drugs and Companies using DAROLUTAMIDE ingredient

NCE-1 date: July, 2023

Market Authorisation Date: 30 July, 2019

Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer

Dosage: TABLET;ORAL

More Information on Dosage

111. List of Nuplazid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7601740 ACADIA PHARMS INC Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
Apr, 2030

(7 years from now)

Drugs and Companies using PIMAVANSERIN TARTRATE ingredient

Market Authorisation Date: 28 June, 2018

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of NUPLAZID before it's patent expiration?
More Information on Dosage

112. List of Nuzyra drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8383610 PARATEK PHARMS INC Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline
Sep, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 2, 2023
Generating Antibiotic Incentives Now (GAIN) Oct 2, 2028

Drugs and Companies using OMADACYCLINE TOSYLATE ingredient

NCE-1 date: October, 2027

Market Authorisation Date: 02 October, 2018

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

113. List of Olumiant drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8158616 ELI LILLY AND CO Azetidine and cyclobutane derivatives as JAK inhibitors
Jun, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) May 10, 2025
New Chemical Entity Exclusivity (NCE) May 31, 2023

Drugs and Companies using BARICITINIB ingredient

NCE-1 date: May, 2022

Market Authorisation Date: 31 May, 2018

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of OLUMIANT before it's patent expiration?
More Information on Dosage

114. List of Ongentys drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10071085 NEUROCRINE Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
Mar, 2030

(7 years from now)

US10583130 NEUROCRINE Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof
Mar, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Apr 24, 2025

Drugs and Companies using OPICAPONE ingredient

NCE-1 date: April, 2024

Market Authorisation Date: 24 April, 2020

Treatment: Method of treating parkinson's disease

Dosage: CAPSULE;ORAL

More Information on Dosage

115. List of Onpattro drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8802644 ALNYLAM PHARMS INC Lipid formulation
Oct, 2030

(7 years from now)

US8158601 ALNYLAM PHARMS INC Lipid formulation
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 10, 2025
New Chemical Entity Exclusivity (NCE) Aug 10, 2023

Drugs and Companies using PATISIRAN SODIUM ingredient

NCE-1 date: August, 2022

Market Authorisation Date: 10 August, 2018

Treatment: Treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

116. List of Onureg drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846628 CELGENE CORP Oral formulations of cytidine analogs and methods of use thereof
Jun, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Sep 1, 2023
Orphan Drug Exclusivity (ODE) Sep 1, 2027

Drugs and Companies using AZACITIDINE ingredient

Market Authorisation Date: 01 September, 2020

Treatment: Continued treatment of adults with acute myeloid leukemia who achieved first complete remission (cr) or cr with incomplete blood count recovery following intensive induction chemotherapy and are not able to complete intensive curative therapy

Dosage: TABLET;ORAL

How can I launch a generic of ONUREG before it's patent expiration?
More Information on Dosage

117. List of Onzetra Xsail drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8899229 CURRAX Powder delivery devices
Aug, 2030

(7 years from now)

US9649456 CURRAX Nasal administration
Oct, 2030

(7 years from now)

US8978647 CURRAX Nasal delivery
Dec, 2030

(7 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: Acute treatment of migraine; Treatment of migraine via delivery of sumatriptan via the nasal cavity; Acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device

Dosage: POWDER;NASAL

More Information on Dosage

118. List of Orbactiv drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9682061 MELINTA THERAP Methods of treating bacterial infections using oritavancin
Apr, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 6, 2019
Generating Antibiotic Incentives Now (GAIN) Aug 6, 2024

Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 06 August, 2014

Treatment: Treatment of bacterial skin and skin structure infections

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

119. List of Orenitram drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410169 UNITED THERAP Compounds and methods for delivery of prostacyclin analogs
Feb, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Oct 18, 2022
Orphan Drug Exclusivity (ODE) Oct 18, 2026

Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient

Market Authorisation Date: 20 December, 2013

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of ORENITRAM before it's patent expiration?
More Information on Dosage

120. List of Orkambi drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8507534 VERTEX PHARMS INC Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
Sep, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8716338 VERTEX PHARMS INC Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
Sep, 2030

(7 years from now)

US8993600 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Dec, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Sep 28, 2023

Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient

Market Authorisation Date: 02 July, 2015

Treatment: Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using the dosage unit of claim 1 of u.s. patent no. 8,716,338; Method of treating cystic fibrosis in patients who have the f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Dosage: TABLET;ORAL

More Information on Dosage

121. List of Osmolex Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8252331 ADAMAS PHARMA Osmotic device containing amantadine and an osmotic salt
Mar, 2030

(7 years from now)

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 February, 2018

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

122. List of Otiprio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8318817 ALK ABELLO Controlled release antimicrobial compositions and methods for the treatment of otic disorders
Apr, 2030

(7 years from now)

Drugs and Companies using CIPROFLOXACIN ingredient

Market Authorisation Date: 10 December, 2015

Treatment: Treatment of otic infection or inflammation

Dosage: INJECTABLE, SUSPENSION;OTIC

More Information on Dosage

123. List of Otovel drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8932610 LABORATORIOS SALVAT Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation
Mar, 2030

(7 years from now)

Drugs and Companies using CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE ingredient

Market Authorisation Date: 29 April, 2016

Treatment: Treatment of acute otitis media

Dosage: SOLUTION/DROPS;OTIC

More Information on Dosage

124. List of Otrexup drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8945063 OTTER PHARMS Hazardous agent injection system
Mar, 2030

(7 years from now)

US8579865 OTTER PHARMS Hazardous agent injection system
Mar, 2030

(7 years from now)

US9421333 OTTER PHARMS Hazardous agent injection system
Mar, 2030

(7 years from now)

US11497753 OTTER PHARMS Hazardous agent injection system
Mar, 2030

(7 years from now)

US8480631 OTTER PHARMS Hazardous agent injection system
Mar, 2030

(7 years from now)

Drugs and Companies using METHOTREXATE ingredient

Market Authorisation Date: 11 October, 2013

Treatment: Subcutaneous injection of methotrexate

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

125. List of Oxycontin drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8894987 PURDUE PHARMA LP Tamper resistant dosage forms
Mar, 2030

(7 years from now)

Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 05 April, 2010

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

126. List of Parsabiv drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9278995 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Jul, 2030

(7 years from now)

US9701712 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Jul, 2030

(7 years from now)

US8377880 KAI PHARMS INC Therapeutic agents for reducing parathyroid hormone levels
Jul, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Feb 7, 2022

Drugs and Companies using ETELCALCETIDE ingredient

NCE-1 date: February, 2021

Market Authorisation Date: 07 February, 2017

Treatment: A method of treating secondary hyperparathyroidism (shpt)

Dosage: SOLUTION;INTRAVENOUS

How can I launch a generic of PARSABIV before it's patent expiration?
More Information on Dosage

127. List of Pennsaid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8546450 HORIZON Treatment of pain with topical diclofenac compounds
Aug, 2030

(7 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Market Authorisation Date: 16 January, 2014

Treatment: Combination use of topical diclofenac on the knee and administration of an oral nsaid.; Use of topical diclofenac on the knee and a second topical agent selected from sunscreen and insect repellant

Dosage: SOLUTION;TOPICAL

How can I launch a generic of PENNSAID before it's patent expiration?
More Information on Dosage

128. List of Pennsaid drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8546450 NUVO PHARMS INC Treatment of pain with topical diclofenac compounds
Aug, 2030

(7 years from now)

Drugs and Companies using DICLOFENAC SODIUM ingredient

Market Authorisation Date: 04 November, 2009

Treatment: Combination use of topical diclofenac on the knee and administration of an oral nsaid.; Use of topical diclofenac on the knee and a second topical agent selected from sunscreen and insect repellant

Dosage: SOLUTION;TOPICAL

How can I launch a generic of PENNSAID before it's patent expiration?